P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

• S. Saraf,
• R. C. Brown,
• R. W. Hagar,
• M. Idowu,
• I. Osunkwo,
• T. A. Kalfa,
• F. A. Kuypers,
• J. Geib,
• P. Schroeder,
• E. Wu,
• P. Kelly,
• M. J. Telen

Affiliations

S. Saraf

1 University of Illinois at Chicago, Chicago

R. C. Brown

2 Children’s Healthcare of Atlanta, Atlanta

R. W. Hagar

3 UCSF Benioff Children’s Hospital San Francisco, Oakland

M. Idowu

4 UTHealth McGovern Medical School, Houston

I. Osunkwo

5 Levine Cancer Institute, Charlotte

T. A. Kalfa

6 Cincinnati Children’s Hospital Medical Center, Cincinnati

F. A. Kuypers

7 University of California, San Francisco

J. Geib

8 Forma Therapeutics, Inc., Watertown

P. Schroeder

8 Forma Therapeutics, Inc., Watertown

E. Wu

8 Forma Therapeutics, Inc., Watertown

P. Kelly

8 Forma Therapeutics, Inc., Watertown

M. J. Telen

9 Duke University Medical Center, Durham, United States of America